Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 9/20 | 0.58 |
| ▸ | IL2 | P60568 | 3/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9907628 | 0.92 | HTR5A (0.67) | HTR5AIL2NR1H2NR1H3TTR | |
| SCHEMBL9907743 | 0.87 | HTR5A (0.58) | HTR5AIL2NR1H2NR1H3KDM4E | |
| SCHEMBL9907635 | 0.83 | HTR5A (0.59) | HTR5AIL2NR1H2 | |
| SCHEMBL9907748 | 0.83 | HTR5A (0.55) | HTR5ANR1H2NR1H3TTRKDM4E | |
| SCHEMBL9907502 | 0.83 | HTR5A (0.67) | HTR5ANR1H2NR1H3NPC1RAB9A | |
| SCHEMBL9907517 | 0.83 | HTR5A (0.63) | HTR5ANPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL9909207 | 0.82 | HTR5A (0.50) | HTR5ANEK1AXLKDM4E | |
| SCHEMBL9907656 | 0.80 | HTR5A (0.61) | HTR5ANR1H2NR1H3ALDH1A1 | |
| SCHEMBL9907709 | 0.80 | HTR5A (0.49) | HTR5ANR1H2NR1H3KDM4EALDH1A1 | |
| SCHEMBL9907625 | 0.80 | HTR5A (0.51) | HTR5ANPC1RAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | HTR5A 1/4885IL2 3643/4885NR1H2 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.